Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Asthma

Personalised medicine approach could benefit people with asthma

A study has suggested that children who received genotype-based prescribing had better health quality of life outcomes than those who received usual care.

Montelukast asthma drug

Source: DR P. MARAZZI / SCIENCE PHOTO LIBRARY

Children who received genotype-based prescribing and carried at least one copy of the A allele in the beta-2 receptor gene rs1042713 were prescribed montelukast for their asthma

Prescribing asthma treatment based on genetic differences could improve outcomes, results presented at the European Respiratory Society International Congress have suggested (8 September 2020)[1].

The study included 241 children aged 12–18 years with asthma, who were receiving an inhaled corticosteroid. They were randomly assigned to receive usual care or genotype-based prescribing, in which those carrying at least one copy of the A allele in the beta-2 receptor gene rs1042713 were prescribed montelukast instead of salmeterol.

After 12 months, the genotype-based group had a small but significant improvement in Asthma Quality of Life Questionnaire (AQLQ) scores than the usual care group  (0.16 on a 7-point scale, 95% confidence interval [CI] 0.00–0.31; P=0.049), although it was below clinical threshold (0.25). When only including those carrying two copies of the A allele (A/A), this difference in AQLQ score increased to 0.42 (95% CI 0.02–0.81; P=0.041).

Previous research has suggested that the A allele of rs1042713 is associated with a poor response to beta-2 agonist medication, which can worsen asthma symptoms. 

“These results are very promising because they show, for the first time, that it could be beneficial to test for certain genetic differences in children with asthma and select medication according to those differences,” said Somnath Mukhopadhyay, the study lead and chair in paediatrics in the Academic Department of Paediatrics at Brighton and Sussex Medical School. ”Larger trials, with a focus on those with poorer asthma control, may help us determine the true benefit for children of prescribing in this way,” he added.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2020.20208418

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.